肿瘤细胞治疗研究
英文原题：Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
⚠ 该试验的登记信息已有 18 个月未更新， 页面上显示的「邀请入组」可能已经失效。联系研究中心之前，建议先到 ClinicalTrials.gov 核对登记原文的最新状态与联系方式。
这是一项分期未标注的注册临床试验，评估细胞治疗用于血液系统恶性肿瘤、实体瘤的安全性、可行性及初步疗效。当前状态：邀请入组。计划入组 50 例。试验地点：美国 · 布法罗（共 1 个中心）。登记号：NCT06925685。
不限性别
纳入标准： * 在既往由Allogene或Servier申办的临床研究中，曾为治疗肿瘤性疾病接受异基因CAR-T 细胞产品输注 排除标准： * 末次接受异基因CAR-T 细胞产品后随访不足12个月；除非获得Allogene医学监查员批准
Inclusion Criteria: * Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study Exclusion Criteria: * Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor
以上为辅助阅读译文。是否适合入组须由主治医生判断，最终以登记平台与研究者确认为准。
主要终点：Incidence of delayed adverse events potentially related to allogeneic CAR T-cell product and allogeneic CAR T-cell product-related SAEs · Up to 15 years post treatment with allogeneic CAR T-cell product；Overall survival (OS) · Up to 15 years post treatment with allogeneic CAR T cell product；Presence of replication competent lentivirus (RCL) in blood · Up to 15 years post treatment with allogeneic CAR T cell product
这是一项针对既往在临床研究中接受过异基因CAR-T 产品的参与者开展的长期随访（LTFU）观察性研究。参与者将在最后一次输注异基因CAR-T 细胞产品后随访15年。
An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infusion of an allogenic CAR T cell product.
MEMBER ACCOUNT
登录成功会直接打开下一页。
